BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 25455006)

  • 1. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
    Yamal JM; Oparil S; Davis BR; Alderman MH; Calhoun DA; Cushman WC; Fendley HF; Franklin SS; Habib GB; Pressel SL; Probstfield JL; Sastrasinh S;
    J Am Soc Hypertens; 2014 Nov; 8(11):808-19. PubMed ID: 25455006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Alderman MH; Piller LB; Ford CE; Probstfield JL; Oparil S; Cushman WC; Einhorn PT; Franklin SS; Papademetriou V; Ong ST; Eckfeldt JH; Furberg CD; Calhoun DA; Davis BR;
    Hypertension; 2012 May; 59(5):926-33. PubMed ID: 22431578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
    Wright JT; Dunn JK; Cutler JA; Davis BR; Cushman WC; Ford CE; Haywood LJ; Leenen FH; Margolis KL; Papademetriou V; Probstfield JL; Whelton PK; Habib GB;
    JAMA; 2005 Apr; 293(13):1595-608. PubMed ID: 15811979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
    Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
    Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
    PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
    Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
    Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
    Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Piller LB; Ford CE; Davis BR; Nwachuku C; Black HR; Oparil S; Retta TM; Probstfield JL;
    J Clin Hypertens (Greenwich); 2006 Sep; 8(9):649-56; quiz 657-8. PubMed ID: 16957427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Muntner P; Levitan EB; Lynch AI; Simpson LM; Whittle J; Davis BR; Kostis JB; Whelton PK; Oparil S
    J Clin Hypertens (Greenwich); 2014 May; 16(5):323-30. PubMed ID: 24739073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
    Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dhruva SS; Huang C; Spatz ES; Coppi AC; Warner F; Li SX; Lin H; Xu X; Furberg CD; Davis BR; Pressel SL; Coifman RR; Krumholz HM
    Hypertension; 2017 Jul; 70(1):94-102. PubMed ID: 28559399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.